Biologic Therapy

The FDA has granted orphan drug designation to a microbiome-modifying biologic to treat Angelman syndrome, according to the manufacturer.

DESTIN, Fla. — New data on discontinuation or dose reduction of biologic therapies has led to a shifting landscape in axial spondyloarthritis management, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

Use of biologics to treat moderate to severe systemic lupus erythematosus increased 45% between 2021 and 2023, according to recent findings from a market analysis conducted by Spherix Global Insights.

Osteochondral defects of the knee articular cartilage are injuries frequently seen in orthopedics and sports medicine.

Between dupilumab, benralizumab and mepolizumab, patients with difficult-to-control asthma had the lowest rate of exacerbations in the first year of dupilumab, according to results published in Annals of the American Thoracic Society.

The FDA has granted priority review to dupilumab to treat adults with uncontrolled COPD with type 2 inflammation, according to a manufacturer-issued press release.

SCOTTSDALE, Ariz. — Although many rheumatologists may not reach for biologic therapies for gout management, interleukin-1 and 6 inhibitors may have utility in managing mobilization flares, according to a speaker here.

Gut microbiota profiles in stool samples of patients with rheumatoid arthritis predicted their response to disease-modifying antirheumatic drugs, according to data in Rheumatology.

Patients with hidradenitis suppurativa are hesitant to use adalimumab — which is recommended as a first-line treatment for the skin condition — as well as other biologics, according to a study.

The prevalence of severe persistent asthma among patients with asthma significantly ranges across the United States, from 19.6% in New Mexico to 31.9% in Alaska, according to a study published in Annals of Allergy, Asthma & Immunology.